RESUMO
Aim To detect the expression of Krupple-like factor 6 ( KLF6) and inducible nitric oxide syn-thase (iNOS) in mouse mononuclear macrophage leukemia cells infected with pseudomonas aeruginosa (PA) supernatant, and to investigate the role of KLF6 protein and iNOS protein in the apoptosis of RAW264. 7 infected with PA supernatant. Methods The effect of PA supernatant on the proliferation of RAW264. 7 was detected by MTT assay. The apoptotic rate was detected by flow cytometry. The morphological changes of RAW264.7 were detected by Hoechst 33342 staining. The effect of PA supernatant on KLF6 and iNOS protein expression was detected by Western blot. Results PA supernatant inhibited the proliferation of RAW264.7 in a concentration- A nd time-depend-ent manner. PA supernatant significantly increased the percentage of RAW264.7 apoptosis and promoted the expression of KLF6 and iNOS. Conclusions PA can inhibit the proliferation of RAW264. 7, which may induce apoptosis through KLF6 and iNOS protein expres-sion.
RESUMO
PURPOSE: Long noncoding RNA 00703 (LINC00703) was found originating from a region downstream of Kruppel-like factor 6 (KLF6) gene, having 2 binding sites for miR-181a. Since KLF6 has been reported as a target of miR-181a in gastric cancer (GC), this study aims to investigate whether LINC00703 regulates the miR-181a/KLF6 axis and plays a functional role in GC pathogenesis.MATERIALS AND METHODS: GC tissues, cell lines, and nude mice were included in this study. RNA binding protein immunoprecipitation (RIP) and pull-down assays were used to evaluate interaction between LINC00703 and miR-181a. Quantitative real-time polymerase chain reaction and western blot were applied for analysis of gene expression at the transcriptional and protein levels. A nude xenograft mouse model was used to determine LINC00703 function in vivo.RESULTS: We revealed that LINC00703 competitively interacts with miR-181a to regulate KLF6. Overexpression of LINC00703 inhibited cell proliferation, migration/invasion, but promoted apoptosis in vitro, and arrested tumor growth in vivo. LINC00703 expression was found to be decreased in GC tissues, which was positively correlated with KLF6, but negatively with the miR-181a levels.CONCLUSIONS: LINC00703 may have an anti-cancer function via modulation of the miR-181a/KLF6 axis. This study also provides a new potential diagnostic marker and therapeutic target for GC treatment.
Assuntos
Animais , Camundongos , Apoptose , Sítios de Ligação , Western Blotting , Linhagem Celular , Proliferação de Células , Expressão Gênica , Xenoenxertos , Imunoprecipitação , Técnicas In Vitro , Camundongos Nus , Reação em Cadeia da Polimerase em Tempo Real , RNA Longo não Codificante , Proteínas de Ligação a RNA , Neoplasias GástricasRESUMO
Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cancer. The aim of this study is to evaluate the level of expression of KLF6 in Caco2 cells treated with Avandia. For this a Immunofluorescence was performed, the Caco2 cells were cultured and treated with Rosiglitazone, another group was treated with Rosiglitazone and GW-9662, inhibitor for Immunofluorescence an anti-KLF6 antibody and a secondary antibody coupled to Alexa-488 was used . Cells were observed in a fluorescence microscope and images were processed. The results show that KLF6 is expressed in the cytoplasm of cells Caco2. Compared to treatment with Avandia, KLF6 increases its expression in the cytoplasm. When cells were treated with GW-9662 inhibitor, an expression of KLF6 in the nucleus was observed. KLF6 expression in the cytoplasm of cells Caco2, could be explained by the knowledge of splicing variants SV1 and SV2, these abnormally accumulate in the cytoplasm and promotes cell growth. It is concluded that in untreated Caco 2 cells, KLF6 is expressed in the cytoplasm. Compared to treatment with Rosiglitazone, KLF6 upregulated in the cytoplasm and compared to treatment with the inhibitor, KLF6 is expressed in the nucleus of Caco 2 cells.
Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cancer. The aim of this study is to evaluate the level of expression of KLF6 in Caco2 cells treated with Avandia. For this a Immunofluorescence was performed, the Caco2 cells were cultured and treated with Rosiglitazone, another group was treated with Rosiglitazone and GW-9662, inhibitor for Immunofluorescence an anti-KLF6 antibody and a secondary antibody coupled to Alexa-488 was used . Cells were observed in a fluorescence microscope and images were processed. The results show that KLF6 is expressed in the cytoplasm of cells Caco2. Compared to treatment with Avandia, KLF6 increases its expression in the cytoplasm. When cells were treated with GW-9662 inhibitor, an expression of KLF6 in the nucleus was observed. KLF6 expression in the cytoplasm of cells Caco2, could be explained by the knowledge of splicing variants SV1 and SV2, these abnormally accumulate in the cytoplasm and promotes cell growth. It is concluded that in untreated Caco 2 cells, KLF6 is expressed in the cytoplasm. Compared to treatment with Rosiglitazone, KLF6 upregulated in the cytoplasm and compared to treatment with the inhibitor, KLF6 is expressed in the nucleus of Caco 2 cells.
Assuntos
Humanos , Adenocarcinoma/metabolismo , Antineoplásicos/farmacologia , Neoplasias do Colo/metabolismo , Fatores de Transcrição Kruppel-Like , Tiazolidinedionas/farmacologia , Apoptose , Células CACO-2 , Linhagem CelularRESUMO
Objective To investigate the effects of Kruppel-like factor 6 (KLF6) on the apoptotic and migration ability of HepG2 cell, and the developmental role of KLF6 on zebrafish liver.Methods Constructed plasmid with shRNA-KLF6 was transfected in HepG2 and L-02.The impacts of loss of KLF6 on HepG2 was investigated by Western bolt, apoptosis analyses, cell cycle detection and scratch experiment;KLF6 morpholino oligonucleotides was microinjected into the Tg(lfabp:eGFP) transgenic zebrafish embryos.The morphant phenotype of the liver was imaged and the protein expression of KLF6 after knockdown of KLF6 was analyzed by Immunofluorescence staining.Results The expression of KLF6 in L-02 was significantly higher than in HepG2.After knockout of KLF6, KLF6 protein expression and apoptosis were significantly reduced.In addition, the cell cycle mainly stated in S phase and the migration ability of HepG2 was enhanced.After klf6 knockdown in transgenic zebrafish larvae, the development of zebrafish liver was delayed and KLF6 expression was obviously decreased in the liver.Conclusions The reduction of KLF6 expression increased the proliferation and migration ability, and reduced the apoptosis of HepG2.Loss of KLF6 affects the development of zebrafish liver, which may open a possibility to use zebrafish as a liver cancer model and for anti-liver cancer drug screening.
RESUMO
El cáncer colorrectal (CCR) constituye el segundo tipo de cáncer más frecuente en la población europea. Actualmente no existe biomarcadores moleculares que se pueden utilizar para la detección temprana del cáncer de CCR. KLF6 es un supresor tumoral relacionado con varios tipos de cánceres. Nuestra hipótesis plantea que KLF6 puede ser un excelente marcador en el diagnóstico precoz de CCR. Para estudiar la implicancia de KLF6 en el CCR, se seleccionaron 15 biopsias de cada estadio (T1,T2 y T3) de los archivos del Servicio de Anatomía Patológica del Hospital Central de la Defensa Gómez-Ulla, las cuales presentaban áreas de tejido afectado (tumor) y áreas sin afectación (no tumorales). Para ello se realizó un estudio histológico, inmunohistoquímico y RT-PCR, basada en la expresión de 3 genes, Ki67 y p53 como marcadores positivos y KLF6 como marcador en estudio. Los resultados mostraron que la expresión de KLF6 está directamente relacionada con el aumento de la malignidad celular en los adenocarcinomas, corroboradas por las RT-PCR, observándose la aparición progresiva de formas de procesado alternativo, no correspondiente a KLF6. Esta proteína, se expresó tanto a nivel citoplasmático como nuclear en los primeros estadios T1 y T2, para desaparecer a nivel nuclear en el estadio más avanzado (T3). Concluimos que KLF6 es un buen marcador tumoral de CCR, debido a que muestra patrones crecientes de expresión a nivel citoplasmático y decrecientes a nivel nuclear...
Colorectal cancer (CRC) is the second most common type of cancer in the European population. Currently there molecular biomarkers that can be used for early detection of cancer of CRC. Is a tumor suppressor KLF6 associated with several types of cancers. Our hypothesis is that KLF6 can be an excellent marker for the early diagnosis of CRC. To study the implication of KLF6 in CRC, we selected 15 biopsies of each stage (T1, T2 and T3) from the archives of the Pathology Department of Defense Central Hospital Gómez-Ulla, which had areas of affected tissue (tumor) and unaffected areas (non-tumor). This study was performed histological, immunohistochemical and RT-PCR, based on the expression of three genes, markers Ki67 and p53 as positive and as a marker in KLF6 study. The results showed that the expression of KLF6 is directly related to increased malignancy cell adenocarcinomas, corroborated by RT-PCR, showing the gradual emergence of alternative forms processing, corresponding to no KLF6. This protein was expressed both cytoplasmic and nuclear in the early stages T1 and T2, disappearing at the nuclear level in the most advanced stage (T3). KLF6 conclude that a good CRC tumor marker because it shows patterns of expression level increased cytoplasmic and nuclear level decreasing...